Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histological confirmation of prostate cancer
Patients receiving androgen deprivation treatment (ADT) with GnRH analogs, GnRH antagonists or bilateral orchiectomy of any duration.
Cohort A: nmCRPC (status post- primary treatment with radical prostatectomy, radiation of any type or both)
* Negative 99mTc-methylene diphosphonate bone scan and CT of the chest abdomen and pelvis within 6 weeks of 18F-DCFPyL PET/CT
* Treatment with ADT with or without a second line novel AR targeted treatment (abiraterone, enzalutamide, or both) or 4 weeks after discontinuation of first generation antiandrogen (bicalutamide , flutamide, nilutamide- one or more permitted) for ≥ 12 months.
* Rising PSA ≥ 10 ng/ml (confirmed by 2 determinations one week apart)
* PSADT ≤ 9 months
Cohort B: mCRPC
* Treatment with ADT with or without abiraterone and or enzalutamide or both for ≥ 6 months and/or 4 weeks after discontinuation of first generation antiandrogen (bicalutamide , flutamide, nilutamide- one or more permitted).
* PSA ≥ 2.0 ng/ml confirmed X 1 week apart, any PSADT
No new therapeutic interventions planned or scheduled to be instituted prior to the course of this study both on cohorts A and B before conventional radiologic progression is evidenced.
Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures.
You may not be if
Patient will be excluded from enrollment if he had a radioisotope within 5 physical half-lives prior to PET imaging
Clareo Health | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
